PPP3CB

PPP3CB (calcineurin A beta) is the catalytic subunit of a Ca2+/calmodulin-regulated serine/threonine protein phosphatase (protein phosphatase-2B) that operates downstream of calcium signaling to control gene-regulatory programs in immune, autophagic, and oncogenic contexts (PMID:8978785, PMID:41876744). It functions as a heterodimer with the calcineurin B regulatory subunit PPP3R1 and, in T lymphocytes, dephosphorylates NF-AT to regulate IL-2 transcription (PMID:8978785). A major characterized output is the control of TFEB-driven autophagic/lysosomal transcription: PPP3CB is the specific calcineurin catalytic isoform that engages TFEB through its LxVP motif-binding site, and lysosomal calcium release via the channel MCOLN1 activates PPP3CB to dephosphorylate TFEB and drive its nuclear translocation and autophagic flux (PMID:41876744). Upon lysosomal damage PPP3CB is recruited by galectin-3 (LGALS3), which it dephosphorylates to promote the LGALS3 open conformer, and serves as a bridge for SMURF1, which ubiquitinates PPP3CB at K146 with K63-linked chains to enhance TFEB recruitment and activation by both PPP3CB and PPP3R1 (PMID:39324484). Through its phosphatase activity PPP3CB also acts in disease-relevant signaling: it maintains E-cadherin and suppresses EMT in kidney tumor cells (PMID:30641937), destabilizes PDHK1 to suppress glycolysis in bladder cancer (PMID:38420800), promotes ATOH8 nuclear translocation to transcriptionally repress Sp1 and limit pancreatic cancer metastasis (PMID:40222712), drives a calcineurin/MEK/ERK pathway underlying EGFR-TKI resistance in NSCLC (PMID:39353739), and promotes angiotensin II-induced vascular remodelling via HB-EGF/EGFR-TGFβ-CTGF signaling (PMID:34228904).

1. 1996 Medium

   Established the basic identity of PPP3CB as a calmodulin-regulated phosphatase and its first substrate, defining its role in calcium-dependent immune gene transcription.

   Evidence Chromosomal localization with biochemical characterization of the calcineurin A beta/PPP3R1 heterodimer and NF-AT dephosphorylation

   PMID:8978785

   Open questions at the time

   • No direct in vitro reconstitution detailed
   • Isoform-specific contribution versus PPP3CA not resolved
   • Structural basis of substrate recognition not defined
2. 2019 Medium

   Showed PPP3CB phosphatase activity directly maintains epithelial identity, extending its role beyond immune signaling into EMT and tumor suppression.

   Evidence Knockdown/overexpression and phosphatase-domain deletion in G401 kidney cells with migration and tumor growth assays

   PMID:30641937

   Open questions at the time

   • Direct phosphatase substrate maintaining E-cadherin not identified
   • Single cell-line context
   • Upstream calcium trigger not defined
3. 2021 Medium

   Defined a physiological in vivo role for PPP3CB in vascular remodelling, linking it to a secreted growth-factor signaling cascade.

   Evidence PPP3CB knockout mice and VSMC assays with pharmacological pathway dissection of HB-EGF/EGFR-TGFβ-CTGF

   PMID:34228904

   Open questions at the time

   • Direct phosphatase substrate connecting PPP3CB to HB-EGF secretion unknown
   • Mechanism of EGFR activation indirect
   • Single lab
4. 2024 High

   Revealed a lysosomal-damage signaling hub in which PPP3CB is both a regulatory phosphatase for galectin-3 and a ubiquitination substrate that scaffolds TFEB activation.

   Evidence Reciprocal Co-IP, K146 site-directed mutagenesis, SMURF1 knockdown/knockout, calcium and lysosomal damage assays

   PMID:39324484

   Open questions at the time

   • Structural basis of K63-ubiquitin-enhanced TFEB recruitment unresolved
   • How phosphatase activity and scaffolding roles are coordinated unclear
   • In vivo relevance not tested
5. 2024 Medium

   Implicated PPP3CB in metabolic reprogramming by linking it to PDHK1 stability and glycolytic suppression.

   Evidence Co-IP, knockdown, glucose/lactate assays and nude-mouse tumorigenesis in bladder cancer cells

   PMID:38420800

   Open questions at the time

   • Whether PDHK1 destabilization is phosphatase-dependent not established
   • Direct versus indirect interaction not distinguished
   • Single cancer context
6. 2024 Medium

   Connected PPP3CB to therapy resistance, showing TKI-induced calcium activates a PPP3CB/MEK/ERK survival pathway.

   Evidence siRNA knockdown, cyclosporin A inhibition, apoptosis assays and mouse models with calcium measurements in NSCLC

   PMID:39353739

   Open questions at the time

   • Direct PPP3CB substrate linking to MEK/ERK not identified
   • Mechanism of calcium elevation by TKI not defined
   • Clinical relevance untested
7. 2025 Medium

   Identified a transcriptional axis in which PPP3CB promotes ATOH8 nuclear entry to repress Sp1 and limit metastasis.

   Evidence LC-MS/MS, Co-IP, confocal imaging, ChIP-seq, luciferase reporter and xenografts in pancreatic cancer

   PMID:40222712

   Open questions at the time

   • Whether ATOH8 translocation requires PPP3CB dephosphorylation unclear
   • Direct ATOH8 phosphosite not mapped
   • Single tumor type
8. 2026 High

   Established isoform specificity and the molecular interface for TFEB regulation, defining the MCOLN1-PPP3CB-TFEB autophagy pathway.

   Evidence PPP3CB/PPP3CA isoform-specific knockdown, LxVP-blocking YLAVP peptide, MCOLN1 inhibitor/agonist, TFEB activity and autophagic flux assays under OGD in neurons

   PMID:41876744

   Open questions at the time

   • Structural detail of the LxVP-binding site engaging TFEB not solved
   • Basis of PPP3CB versus PPP3CA selectivity unknown
   • Relationship to the LGALS3/SMURF1 lysosomal pathway not integrated

• It remains unresolved how PPP3CB's phosphatase activity, scaffolding function, and ubiquitin-dependent regulation are mechanistically coordinated across its diverse signaling contexts, and which direct substrates underlie most of its disease phenotypes.
• Direct substrates for most cancer/vascular phenotypes unmapped
• No structural model of substrate or LxVP recognition
• Integration of distinct pathways into one regulatory logic absent